+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2020 Update

  • ID: 4372868
  • Company Profile
  • June 2020
  • 40 Pages
  • GlobalData

FEATURED COMPANIES

  • Allergan Plc
  • Graybug Vision Inc
  • Mati Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Ocular Therapeutix Inc (Ocular Therapeutix), formerly I-Therapeutix Inc, is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical ocular inflammation and pain. Its pipeline products include OTX-TP, used for treating glaucoma and ocular hypertension; OTX-BPI, targeting acute ocular pain; OTX-BDI, against post-op pain, inflammation and anti-bacterial infections; OTX-KTO for treating allergic conjunctivitis; OTX-CSI, against dry eye. It also develops intracameral implants for treating multiple eye disorders. The company works in collaboration with Regeneron Pharmaceuticals Inc to develop formulations for the treatment of wet AMD and other serious retinal diseases. Ocular Therapeutix is headquartered in Bedford, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Ocular Therapeutix Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan Plc
  • Graybug Vision Inc
  • Mati Therapeutics Inc
Ocular Therapeutix Inc Company Overview
  • Ocular Therapeutix Inc Company Snapshot
  • Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Ocular Therapeutix Inc – Pipeline Analysis Overview
  • Ocular Therapeutix Inc - Key Facts
  • Ocular Therapeutix Inc - Major Products and Services
  • Ocular Therapeutix Inc Pipeline Products by Development Stage
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Ocular Therapeutix Inc Pipeline Products Overview
  • DEXTENZA
  • DEXTENZA Product Overview
  • DEXTENZA Clinical Trial
  • OTX-CSI
  • OTX-CSI Product Overview
  • OTX-IVT
  • OTX-IVT Product Overview
  • OTX-MP
  • OTX-MP Product Overview
  • OTX-TIC
  • OTX-TIC Product Overview
  • OTX-TIC Clinical Trial
  • OTX-TKI
  • OTX-TKI Product Overview
  • OTX-TKI Clinical Trial
  • OTX-TP
  • OTX-TP Product Overview
  • OTX-TP Clinical Trial
  • Ocular Therapeutix Inc - Key Competitors
  • Ocular Therapeutix Inc - Key Employees
  • Ocular Therapeutix Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Ocular Therapeutix Inc, Recent Developments
  • Mar 12, 2020: Ocular Therapeutix reports fourth quarter and year end 2019 financial results and business update
  • Mar 03, 2020: Ocular Therapeutix announces preliminary fourth quarter 2019 net product revenue
  • Nov 12, 2019: Ocular Therapeutix reports third quarter 2019 financial results and business update
  • Nov 08, 2019: Ocular Therapeutix announces strategic update and operational restructuring
  • Oct 01, 2019: Ocular Therapeutix announces permanent J-code for DEXTENZA (dexamethasone ophthalmic insert) effective October 1, 2019
  • Aug 07, 2019: Ocular Therapeutix reports second quarter 2019 financial results and business update
  • Jul 26, 2019: Ocular Therapeutix announces early assignment of permanent and specific J-Code (J1096) for DEXTENZA (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
  • Jul 11, 2019: Ocular Therapeutix announces Christopher White as Senior Vice President, Head of Business and Corporate Development
  • Jul 09, 2019: Ocular Therapeutix announces Patricia Kitchen as Chief Operations Officer
  • Jun 21, 2019: Ocular Therapeutix announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the treatment of Ocular Inflammation following Ophthalmic Surgery
Appendix
  • Methodology
  • About the Publisher
  • Contact
  • Disclaimer
List of Tables
  • Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Ocular Therapeutix Inc Pipeline Products by Equipment Type
  • Ocular Therapeutix Inc Pipeline Products by Indication
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
  • Ocular Therapeutix Inc, Key Facts
  • Ocular Therapeutix Inc, Major Products and Services
  • Ocular Therapeutix Inc Number of Pipeline Products by Development Stage
  • Ocular Therapeutix Inc Pipeline Products Summary by Development Stage
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
  • Ocular Therapeutix Inc Ongoing Clinical Trials Summary
  • DEXTENZA - Product Status
  • DEXTENZA - Product Description
  • DEXTENZA - CLN-0052, A Multi-center, Randomized, Double-masked, Vehicle Controlled Phase III Study Evaluation the Efficacy and Safety of OTX-DP for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (Ora-CAC)
  • DEXTENZA - Evaluation of DEXTENZA on the Management of Pain and Inflammation in Patients with Anterior Uveitis Compared to Standard of Care Topical Corticosteroids
  • OTX-CSI - Product Status
  • OTX-CSI - Product Description
  • OTX-IVT - Product Status
  • OTX-IVT - Product Description
  • OTX-MP - Product Status
  • OTX-MP - Product Description
  • OTX-TIC - Product Status
  • OTX-TIC - Product Description
  • OTX-TIC - To Evaluate the Safety, Efficacy, Durability, and Tolerability of OTX-TIC in Patients with Primary Open-angle Glaucoma or Ocular Hypertension
  • OTX-TKI - Product Status
  • OTX-TKI - Product Description
  • OTX-TKI - A Phase 1 Open-label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects with Neovascular Age-related Macular Degeneration (AMD)
  • OTX-TP - Product Status
  • OTX-TP - Product Description
  • OTX-TP - A Prospective, Multicenter, Open Label Extension Study to Evaluate the Long Term Safety of OTX-TP
  • OTX-TP - Non-significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug
  • Ocular Therapeutix Inc, Key Employees
  • Ocular Therapeutix Inc, Other Locations
  • Ocular Therapeutix Inc, Subsidiaries
  • Glossary
List of Figures
  • Ocular Therapeutix Inc Pipeline Products by Equipment Type
  • Ocular Therapeutix Inc Pipeline Products by Development Stage
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Allergan Plc
  • Mati Therapeutics Inc
  • Graybug Vision Inc
  • EyePoint Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll